HOWREY & SIMON

RECEIVED

Attorneys at Law 1299 Pennsylvania Ave., NW Washington, DC 20004-2402 (202) 783-0800 FAX (202) 383-6610

November 12, 1997

MATHIX CUSTOMER SERVICE CENTER

NOV. 1:2 1997.

Assistant Commissioner for Patents Washington, D.C. 20231
Batch No.: T15

VIA HAND CARRY Bldg.: Crystal Mall 1 Room: 7C11

ATTENTION: EXAMINER J. MCKANE GROUP ART UNIT: 1201

Re:

Allowed U.S. Utility Patent Application

Appl. No. 08/808,261; Filed: February 28, 1997

For: Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles

Inventors:

Mesens et al.

Our Ref:

00166.0051.0002 (New)

1611.0510002 (Old)

Sir:

Transmitted herewith for appropriate action by the U.S. Patent and Trademark Office (PTO) are the following documents:

- 1. Form PTO-1083 (in duplicate);
- 2. Amendment Under 37 C.F.R. § 1.312(a); and
- 3. Return post card.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

 \circ

HOWREY & SIMON

Assistant Commissioner for Patents November 12, 1997 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038. A duplicate copy of this letter is enclosed.

Respectfully submitted,

Andrea G. Reister (Reg. No. 36,253)

Enclosures

PRECEIVED

MOV 1 2 1997

SERVICE CENTRAL

DUA 140. 34

1299 Pennsylvania Avenue, 14.W. Washington, D.C. 20004-2402 (202) 783-0800

FORM PTO-1083

Attorney Docket No. 00166,0051,0002

In re application of MESENS et al.

Appl. No. 08/808,261

Filed: February 28, 1997

For: Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles

THE ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

Sir

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- No additional claim fee is required.

The claim fee has been calculated as shown below:

(Col. 1)					(Col. 2)		(Col. 3)		
	Claims Remaining After Amendment			Highest No. Previously Paid For		Present Extra			
TOTAL	*	22	MINUS	**	20	1	2		
INDEP.	*	5	MINUS	**	3	=	2		
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM									

SMALL ENTITY						
Rate	Addit. Fee					
x 11 =	\$	00.00				
x 41 =	\$	00.00				
+135 =	\$	00.00				
Total Addit. Fee	s	00.00				

SMALL ENTITY							
Rate	Addit. Fee						
x 22 =	\$	44.00					
x 82 =	\$	164.00					
+ 270 =	\$	00.00					
TOTAL	\$	208.00					

OTHER THAN A

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

 The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.
- <u>X</u> Please charge my Deposit Account No. <u>08-3038</u> in the amount of \$208.00 . A duplicate copy of this sheet is attached.
- A check in the amount of \$__.00 is attached.
- <u>xx</u> The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <u>08-3038</u>. A duplicate copy of this sheet is attached.
 - xx Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
 - <u>xx</u> Any patent application processing fees under 37 CFR 1.17.

Date Nov. 12 1997

Andrea G. Reister (Reg. No. 36,253)

Or

OR